Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets
00:35 EDT 13 Aug 2012 | SCRIP
The publicly-traded Novogen oncology spin-out MEI Pharma has acquired pracinostat (SB939), an oral histone deacetylase (HDAC) inhibitor, for just $500,000 in MEI stock upfront, from Singapore-based S*BIO, as the private company's investors divest the..
Original Article: Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets
More From BioPortfolio on "Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
